GSK plans to sell its 4.2% stake in spun-off Haleon.

GSK plans to sell its entire remaining 4.2% stake in Haleon, a consumer health business it spun off in July 2022. This follows previous stake sales in May, October, and January. The latest sale, conducted through a placing of ordinary shares to institutional investors, will allow GSK to focus on vaccines and infectious diseases, and fund deals to enhance its drug pipeline.

May 16, 2024
8 Articles

Further Reading